Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to $685–$705 million, with gross margins in the low 90s and positive operating cash flow of $37 million in H1 2026. Recent retina acquisitions (iRenix, and Alkeus) are milestone-heavy, minimizing upfront risk and leveraging a targeted commercial infrastructure for future launches.
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.48 per share a year ago.
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. TARS reiterates 2026 Xdemvy net sales guidance of $670M–$700M, with Q2'26 prescription data indicating a potential recovery in Xdemvy and the ability to meet 2026 guidance. The iRenix Medical acquisition expands the pipeline with IRX-101, an ocular antiseptic, though revenues are several years out.
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged 2026 revenue guidance ($670–$700M) disappointed, implying 18% annualized growth from the current quarterly run-rate. TARS is building a robust distribution moat, with nearly half of targeted ECPs prescribing Xdemvy weekly and direct-to-consumer activation up 40% QoQ.
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
